Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02839785
Other study ID # ANTALKINECP RB15.213
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 29, 2017
Est. completion date September 19, 2018

Study information

Verified date September 2018
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SPARCLE 1 and 2 studies followed a cohort of 818 children with cerebral palsy (CP) between 8 and 12 (SPARCLE 1) and 13 and 18 years old (SPARCLE 2) interviewed at home. The prevalence of pain in these populations was respectively 60 and 69% while it is about 35% in typically developed children of the same age.

The main location of the pain for 60% of children with CP was the lower limbs, caused by musculoskeletal pain and movement (for those who can) and therapeutic procedures. In SPARCLE 2, 50% of the children complained about pain during physical therapy.

If the pain is part of the management of physiotherapy, a recent review showed that for a condition such as chronic back pain, the level of evidence of the effectiveness of physiotherapy techniques in reducing pain is low. The effectiveness of these techniques would include higher efficacy on anxiety than pain itself.

Despite significant involvement of physiotherapists in the management of pain, the focus on pain should increase, in particular taking into account the procedural/induced pain (caused by treatment).

In addition to drugs, physical methods (analgesic therapy) or psychotherapy are used to reduce the pain of children during medical procedures. For the latter most of them require the presence of two individuals to provide the therapy. This is unsuited for out-patient care provided to the majority of children with CP.

Non steroid anti-inflammatory drug (NSAIDs), are first recommended, alone or in combination with the treatment of several indications in child pain (migraine, postoperative pain, etc.). Ibuprofen is commonly used in children during painful procedures and represented the 4th molecule among prescribed per os analgesic drugs in 2008 in the United States.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date September 19, 2018
Est. primary completion date September 19, 2018
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria:

- Cerebral palsy hemiplegic diplegic or tetraplegic spastic or not.

- Children who feel pain during the pre-screening physiotherapy session with a VAS score above 2.

- Aged 6 to 17 years of both gender.

- Ability to express his/her pain and to measure its intensity with VAS.

- Informed and signed (parents, investigator and child if possible).

Exclusion Criteria:

- Lack of physiotherapy.

- Analgesic treatment already available or stopped in the last month.

- Scheduled surgery procedure or botulinum toxin injection during the period of the assessment of pain (around 5 month)

- The last botulinum toxin injection in two months before the inclusion

- Child who feel pain with EVA score superior or equal to 4 at the time of the inclusion outside the sessions of physiotherapy

- Child unable to cooperate.

- Severe infection or instable vital functions.

- Hypersensitivity to ibuprofen or any of the constituents in the product.

- History of allergy or asthma triggered by taking ibuprofen or substances of near activity such as other NSAIDs and aspirin.

- Allergy to other component of treatment.

- History of upper gastrointestinal bleeding or perforation, related to previous NSAID therapy.

- Active gastrointestinal ulcer.

- Severe hepatic failure.

- Severe renal failure.

- Uncontrolled severe cardiac failure.

- Systemic Lupus Erythematosus.

- Regular intake of ibuprofen

Randomisation Criteria:

• Child who feel pain during the physiotherapy session with a mean VAS score above 3 during the screening phase.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibuprofen
the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
Placebo
the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.

Locations

Country Name City State
France Hôpital Morvan - CHRU Brest Brest
France Hopitaux de Saint-Maurice Saint-Maurice
France Ch Lannion-Trestel Trevou-Treguignec

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of at least 20% of the average VAS between the run-in phase and the treatment phase (placebo and ibuprofen) 5 months
Secondary Pain The pain reduction assessed by the Child health questionnaire 5 months
Secondary Anxiety The anxiety reduction assessed by a VAS scale. 5 months
Secondary Quality of life The increase in quality of life assessed by the CP Child. 5 months
Secondary Incidence of adverse events 5 months
See also
  Status Clinical Trial Phase
Recruiting NCT05317234 - Genetic Predisposition in Cerebral Palsy N/A
Recruiting NCT05576948 - Natural History of Cerebral Palsy Prospective Study
Completed NCT04119063 - Evaluating Wearable Robotic Assistance on Gait Early Phase 1
Completed NCT03264339 - The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy N/A
Completed NCT05551364 - Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy N/A
Completed NCT03902886 - Independent Walking Onset of Children With Cerebral Palsy
Recruiting NCT05571033 - Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy N/A
Not yet recruiting NCT04081675 - Compliance in Children With Cerebral Palsy Supplied With AFOs
Completed NCT02167022 - Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy N/A
Completed NCT04012125 - The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy N/A
Enrolling by invitation NCT05619211 - Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities Phase 1
Completed NCT04489498 - Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
Completed NCT03677193 - Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy N/A
Recruiting NCT06450158 - Robot-assisted Training in Children With CP N/A
Completed NCT04093180 - Intensive Neurorehabilitation for Cerebral Palsy N/A
Completed NCT02909127 - The Pediatric Eating Assessment Tool
Not yet recruiting NCT06377982 - Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy Phase 1
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT03183427 - Corpus Callosum Size in Patients With Pineal Cyst N/A
Active, not recruiting NCT03078621 - Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy Phase 1/Phase 2